Four years af­ter Roche deal, lit­tle gly­co-fo­cused biotech lands new dis­cov­ery deal with Astel­las

Putting im­muno-on­col­o­gy front and cen­ter in its R&D strat­e­gy, Astel­las has brought in a low-pro­file team to help hunt for its next wave of ther­a­pies.

Its part­ner of choice is a lit­tle biotech called GO Ther­a­peu­tics, whose spe­cial­ty is mak­ing an­ti­body-based drugs that specif­i­cal­ly tar­get can­cer gly­co­pro­teins. Where­as GO will be tasked with iden­ti­fy­ing an­ti­bod­ies to two tar­gets, Astel­las will be re­spon­si­ble for the sub­se­quent re­search, clin­i­cal de­vel­op­ment as well as com­mer­cial­iza­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER